Aytu BioPharma (NASDAQ:AYTU) Share Price Crosses Below 200-Day Moving Average – Here’s What Happened

Aytu BioPharma, Inc. (NASDAQ:AYTU) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.36 and traded as low as $1.40. Aytu BioPharma shares last traded at $1.44, with a volume of 12,010 shares traded.

Aytu BioPharma Trading Up 2.5 %

The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.80 and a current ratio of 0.99. The stock has a market capitalization of $8.82 million, a P/E ratio of -1.17 and a beta of -1.40. The stock has a 50-day moving average price of $1.82 and a two-hundred day moving average price of $2.36.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings results on Thursday, September 26th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.37). Aytu BioPharma had a negative net margin of 8.28% and a negative return on equity of 21.89%. The company had revenue of $17.98 million during the quarter.

Hedge Funds Weigh In On Aytu BioPharma

A number of institutional investors have recently bought and sold shares of AYTU. Dimensional Fund Advisors LP grew its holdings in shares of Aytu BioPharma by 54.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock worth $69,000 after acquiring an additional 8,311 shares during the period. Armistice Capital LLC purchased a new position in shares of Aytu BioPharma in the 2nd quarter valued at approximately $736,000. Finally, Stonepine Capital Management LLC boosted its position in shares of Aytu BioPharma by 6.0% during the third quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock valued at $1,177,000 after purchasing an additional 28,489 shares in the last quarter. 33.49% of the stock is owned by institutional investors.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.